U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249905) titled 'This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma' on Nov. 18.
Brief Summary: This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Waldenstrom Macroglobulinemia (WM)
DLBCL - Diffuse Large B Cell Lymphoma
PMBCL
HGBCL
FL Lymphoma
Lymphoplasmacytic Lymphoma
Follicular Lymphoma (FL)
Intervention:
DRUG: MDX2003
MDX2003 intravenous infusion
Recruitment Status: NOT_YET_REC...